research use only

Enarodustat (JTZ-951) HIF inhibitor

Name: Enarodustat (JTZ-951)
Brand: Selleck Chemicals
SKU: S9656
Availability: InStock
Rating: 5 (2 reviews)

Cat.No.S9656

Enarodustat (JTZ-951) is a potent and orally active HIF prolyl hydroxylase inhibitor with IC50 of 0.22 μM for PHD2 and EC50 of 5.7 μM for EPO release from Hep3B cells. Enarodustat has the potential for the treatment of renal anemia.

Chemical Structure

Molecular Weight: 340.33

Jump to

Quality Control

Batch: S965601 DMSO]68 mg/mL]false]Ethanol]2.5 mg/mL]false]Water]Insoluble]false Purity: 99.95%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS/MSDS
Datasheet

99.95

Related Targets	EGFR VEGFR JAK FGFR PDGFR Src FLT3 HER2 FLT Bcr-Abl
Other HIF Inhibitors	PT2399 PX-478 Dihydrochloride BAY 87-2243 KC7F2 Molidustat (BAY 85-3934) IOX2 CAY10585 (LW 6) PT2385 IDF-11774 Daprodustat (GSK1278863)

Solubility

In vitro
Batch:

DMSO : 68 mg/mL (199.8 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 2.5 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	340.33	Formula	C₁₇H₁₆N₄O₄	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1262132-81-9	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	PHD2 (Cell-free assay) 0.22 μM EPO release from Hep3B cells (Cell-based assay) 5.7 μM(EC50)
In vitro	Enarodustat (JTZ-951) inhibits PHD2 with IC50 of 0.22 μM and the EPO release from Hep3B cells with EC50 of 5.7 μM.
In vivo	Enarodustat (JTZ-951), with a 5-phenethyl substituent on the triazolopyridine group, increases hemoglobin levels with daily oral dosing in rats. It is rapidly absorbed after oral administration and disappears shortly thereafter, which can be advantageous in terms of safety. This compound is selected as a clinical candidate.
References	[1] https://pubmed.ncbi.nlm.nih.gov/29259755/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-07-28)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06725810	RECRUITING	Chronic Kidney Disease Associated Anemia	Shanghai Zhongshan Hospital	2025-03-27	PHASE4
NCT07522996	WITHDRAWN	Transfusion-dependent Non-severe Aplastic Anemia	Peking Union Medical College Hospital	2026-06	PHASE3
NCT07548671	NOT_YET_RECRUITING	Transfusion-dependent Non-severe Aplastic Anemia	Peking Union Medical College Hospital	2026-04	PHASE3
NCT07079579	NOT_YET_RECRUITING	Renal Anemia in Non-dialysis Chronic Kidney Disease	Shenzhen Salubris Pharmaceuticals Co., Ltd.	2025-08	PHASE4
NCT06737081	RECRUITING	Anemia	Shenzhen Salubris Pharmaceuticals Co., Ltd.	2024-09-14	PHASE2
NCT04027517	COMPLETED	Anemia of Chronic Kidney Disease	JW Pharmaceutical	2019-01-15	PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):